Adherence to clozapine vs. other antipsychotics in schizophrenia

Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®). Methods In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherenc...

Full description

Saved in:
Bibliographic Details
Published inActa Psychiatrica Scandinavica Vol. 142; no. 2; pp. 87 - 95
Main Authors Takeuchi, H., Borlido, C., Sanches, M., Teo, C., Harber, L., Agid, O., Remington, G.
Format Journal Article
LanguageEnglish
Published Aalborg Wiley 01.08.2020
Blackwell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®). Methods In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively. Results A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence). Conclusion Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.
AbstractList BackgroundTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®).MethodsIn outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.ResultsA total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).ConclusionFindings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.
To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS® ).BACKGROUNDTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS® ).In outpatients with schizophrenia, we conducted a 3-month prospective study investigating antipsychotic adherence with EAM (eCAP® ). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.METHODSIn outpatients with schizophrenia, we conducted a 3-month prospective study investigating antipsychotic adherence with EAM (eCAP® ). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).RESULTSA total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.CONCLUSIONFindings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.
Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®). Methods In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively. Results A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence). Conclusion Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.
Author Carol Borlido
Gary Remington
Marcos Sanches
Hiroyoshi Takeuchi
Ofer Agid
Lillian Harber
Celine Teo
Author_xml – sequence: 1
  givenname: H.
  orcidid: 0000-0002-8844-4786
  surname: Takeuchi
  fullname: Takeuchi, H.
  organization: Centre for Addiction and Mental Health
– sequence: 2
  givenname: C.
  surname: Borlido
  fullname: Borlido, C.
  organization: Centre for Addiction and Mental Health
– sequence: 3
  givenname: M.
  surname: Sanches
  fullname: Sanches, M.
  organization: Centre for Addiction and Mental Health
– sequence: 4
  givenname: C.
  surname: Teo
  fullname: Teo, C.
  organization: Centre for Addiction and Mental Health
– sequence: 5
  givenname: L.
  surname: Harber
  fullname: Harber, L.
  organization: Centre for Addiction and Mental Health
– sequence: 6
  givenname: O.
  surname: Agid
  fullname: Agid, O.
  organization: University of Toronto
– sequence: 7
  givenname: G.
  orcidid: 0000-0001-9433-9416
  surname: Remington
  fullname: Remington, G.
  email: Gary.Remington@camh.ca
  organization: Centre for Addiction and Mental Health
BackLink https://cir.nii.ac.jp/crid/1872272492558869760$$DView record in CiNii
BookMark eNp9kF1LwzAUhoMoOOdu_AUFvRChM0nzeecYfsFAQQXvSpqmNNIltemU7debWb0ZYi5OSM7zHA7vEdh33hkAThCcongulW7DFGUYij0wQgzCFBLC98EIQohSJuHrIZiEYIv4hFIIJEfgalbWpjNOm6T3iW78RrXWmeQjTBPfx1aiXG_bsNa1760OiXVJ0LXd-LaOmlXH4KBSTTCTn3sMXm6un-d36eLh9n4-W6SaYClSVpSVkSXjFa04r8qCF6QSGBdUS1UyyjTnmmKDSyglxZjxIn4WspRRo6LKxuB8mNt2_n1lQp8vbdCmaZQzfhVyTDBkGeaER_R0B33zq87F7SKVUYgYYyRScKB050PoTJVr26veetd3yjY5gvk21Xybav6dalQudpS2s0vVrf-G0QB_2sas_yHz2fzx6dc5GxxnbVxnW5HgGHNMJKZUCCY5g9kXaAKTrg
CitedBy_id crossref_primary_10_1111_acps_13394
crossref_primary_10_1016_j_schres_2023_07_002
crossref_primary_10_1186_s12888_021_03037_0
crossref_primary_10_1016_j_schres_2021_07_024
crossref_primary_10_1097_JCP_0000000000001804
crossref_primary_10_2147_PPA_S495254
crossref_primary_10_1177_0004867421998800
crossref_primary_10_1177_20451253211032053
crossref_primary_10_1016_j_schres_2023_06_005
crossref_primary_10_1080_08039488_2022_2160878
crossref_primary_10_1016_j_schres_2021_08_017
crossref_primary_10_1016_j_schres_2023_11_010
crossref_primary_10_1016_j_schres_2022_08_013
crossref_primary_10_1093_schbul_sbab103
crossref_primary_10_2147_NDT_S402945
crossref_primary_10_1016_j_schres_2022_07_014
crossref_primary_10_1111_acps_13411
crossref_primary_10_1093_schizbullopen_sgab048
crossref_primary_10_3389_fpsyt_2022_1021780
crossref_primary_10_7759_cureus_25765
crossref_primary_10_1136_bmjopen_2024_085956
crossref_primary_10_1016_j_euroneuro_2024_04_012
crossref_primary_10_1192_bjp_2022_1
crossref_primary_10_1097_JCP_0000000000001673
crossref_primary_10_1097_JCP_0000000000001671
Cites_doi 10.1016/j.schres.2006.11.015
10.2147/NDT.S39303
10.4088/JCP.v65n0311
10.1097/YIC.0000000000000188
10.1192/bjp.156.6.798
10.1016/j.schres.2013.02.016
10.4088/JCP.v69n0107
10.1016/j.schres.2005.10.015
10.1016/j.schres.2017.06.026
10.1176/appi.ajp.158.8.1305
10.1016/j.ijcard.2016.04.082
10.1093/schbul/sbj067
10.1001/archpsyc.1988.01800330013001
10.1038/clpt.2014.59
10.1016/j.psychres.2004.11.002
10.1176/ajp.2006.163.4.600
10.1016/j.schres.2008.09.007
10.1007/s40263-020-00713-9
10.1176/appi.ajp.158.4.518
10.1177/2045125312474019
10.2147/PPA.S124658
10.18553/jmcp.2016.22.11.1349
10.1016/j.schres.2011.11.008
10.1017/S0033291700050182
10.1176/ps.2007.58.9.1187
10.1176/appi.ps.55.8.886
10.1592/phco.2005.25.9.1242
10.1016/j.psychres.2014.11.002
10.1016/j.psychres.2019.01.110
ContentType Journal Article
Copyright 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2020 John Wiley & Sons A/S
2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2020 John Wiley & Sons A/S
– notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DBID RYH
AAYXX
CITATION
7TK
K9.
7X8
DOI 10.1111/acps.13208
DatabaseName CiNii Complete
CrossRef
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1600-0447
EndPage 95
ExternalDocumentID 10_1111_acps_13208
ACPS13208
Genre article
GrantInformation_xml – fundername: Canadian Institutes of Health Research
  funderid: 201011
GroupedDBID ---
-~X
.3N
.GA
05W
0R~
10A
1OC
23M
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABIVO
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACHQT
ACMXC
ACPOU
ACPRK
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGYGG
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DUUFO
EAD
EAP
EAS
EBC
EBD
EBS
EMB
EMK
EMOBN
EPS
ESX
EX3
F00
F01
F04
F5P
FUBAC
FZ0
G-S
GODZA
H.X
HGLYW
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
ROL
RX1
RYH
SUPJJ
SV3
TEORI
TUS
UB1
UPT
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
YF5
ZZTAW
~IA
~WT
.55
.GJ
.Y3
1OB
31~
3O-
53G
AANHP
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AEUQT
AFFNX
AFPWT
AHEFC
ASPBG
AVWKF
AZFZN
CAG
COF
EJD
FEDTE
HF~
HVGLF
LW6
OHT
PALCI
RIWAO
RJQFR
SAMSI
WRC
WUP
X7M
ZGI
ZXP
AAYXX
AGQPQ
CITATION
7TK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
K9.
7X8
ID FETCH-LOGICAL-c4298-6bdfe9d67f5f77fdb7b4f822b5c9ad656c77c52e2d09952267b656b9d9fe958f3
IEDL.DBID DR2
ISSN 0001-690X
1600-0447
IngestDate Fri Jul 11 10:58:39 EDT 2025
Wed Aug 13 04:51:21 EDT 2025
Thu Apr 24 23:04:25 EDT 2025
Tue Jul 01 01:06:48 EDT 2025
Wed Jan 22 16:33:29 EST 2025
Thu Jun 26 22:57:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4298-6bdfe9d67f5f77fdb7b4f822b5c9ad656c77c52e2d09952267b656b9d9fe958f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ORCID 0000-0002-8844-4786
0000-0001-9433-9416
PQID 2435016664
PQPubID 33508
PageCount 9
ParticipantIDs proquest_miscellaneous_2420632747
proquest_journals_2435016664
crossref_citationtrail_10_1111_acps_13208
crossref_primary_10_1111_acps_13208
wiley_primary_10_1111_acps_13208_ACPS13208
nii_cinii_1872272492558869760
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-08-01
August 2020
2020-08-00
20200801
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Aalborg
PublicationPlace_xml – name: Aalborg
PublicationTitle Acta Psychiatrica Scandinavica
PublicationYear 2020
Publisher Wiley
Blackwell Publishing Ltd
Publisher_xml – name: Wiley
– name: Blackwell Publishing Ltd
References 2004; 65
2015; 225
2005; 133
2006; 32
1976
2009
2007; 90
2013; 146
2020; 34
1983; 13
2007; 58
2013; 9
2005; 25
2006; 82
1998; 59
2004; 55
2018; 193
2020; 3
2012; 134
2001
2000
2017; 11
2017; 32
2006; 163
2008; 69
1988; 45
2016; 216
2009; 107
1990; 156
2014; 95
2001; 158
2019; 275
2016; 22
e_1_2_9_30_1
Guy W (e_1_2_9_24_1) 1976
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
Bellack AS (e_1_2_9_28_1) 2009
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
Sheehan DV (e_1_2_9_22_1) 1998; 59
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_21_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
Appelbaum PS (e_1_2_9_23_1) 2001
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 216
  start-page: 104
  year: 2016
  end-page: 109
  article-title: Impact of once‐ or twice‐daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta‐regression analysis
  publication-title: Int J Cardiol
– volume: 59
  start-page: 22
  year: 1998
  end-page: 33
  article-title: The mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10
  publication-title: J Clin Psychiatry
– volume: 146
  start-page: 196
  year: 2013
  end-page: 200
  article-title: Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®)
  publication-title: Schizophr Res
– volume: 32
  start-page: 715
  year: 2006
  end-page: 723
  article-title: Randomized controlled trial of effect of prescription of clozapine versus other second‐generation antipsychotic drugs in resistant schizophrenia
  publication-title: Schizophr Bull
– volume: 158
  start-page: 1305
  year: 2001
  end-page: 1313
  article-title: A double‐blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
  publication-title: Am J Psychiatry
– year: 2001
– volume: 225
  start-page: 14
  year: 2015
  end-page: 30
  article-title: A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia‐spectrum disorders
  publication-title: Psychiatry Res
– start-page: 1
  year: 2009
  end-page: 48
  article-title: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness
  publication-title: J Clin Psychiatry
– year: 2000
– volume: 133
  start-page: 129
  year: 2005
  end-page: 133
  article-title: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia
  publication-title: Psychiatry Res
– volume: 90
  start-page: 229
  year: 2007
  end-page: 237
  article-title: The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia
  publication-title: Schizophr Res
– volume: 69
  start-page: 47
  year: 2008
  end-page: 53
  article-title: A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia
  publication-title: J Clin Psychiatry
– volume: 65
  start-page: 354
  year: 2004
  end-page: 360
  article-title: Adherence to conventional and atypical antipsychotics after hospital discharge
  publication-title: J Clin Psychiatry
– volume: 275
  start-page: 149
  year: 2019
  end-page: 154
  article-title: Reasons for clozapine discontinuation in patients with treatment‐resistant schizophrenia
  publication-title: Psychiatry Res
– volume: 156
  start-page: 798
  year: 1990
  end-page: 808
  article-title: Insight and psychosis
  publication-title: Br J Psychiatry
– volume: 134
  start-page: 226
  year: 2012
  end-page: 231
  article-title: Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia
  publication-title: Schizophr Res
– volume: 193
  start-page: 114
  year: 2018
  end-page: 118
  article-title: Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): a six‐month post‐discharge prospective study
  publication-title: Schizophr Res
– volume: 45
  start-page: 789
  year: 1988
  end-page: 796
  article-title: Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine
  publication-title: Arch Gen Psychiatry
– volume: 11
  start-page: 449
  year: 2017
  end-page: 468
  article-title: Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness
  publication-title: Patient Prefer Adherence
– volume: 55
  start-page: 886
  year: 2004
  end-page: 891
  article-title: Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia
  publication-title: Psychiatr Serv
– volume: 107
  start-page: 213
  year: 2009
  end-page: 217
  article-title: Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables
  publication-title: Schizophr Res
– volume: 58
  start-page: 1187
  year: 2007
  end-page: 1192
  article-title: Relationships among subjective and objective measures of adherence to oral antipsychotic medications
  publication-title: Psychiatr Serv
– volume: 32
  start-page: 337
  year: 2017
  end-page: 342
  article-title: Patient attitudes to clozapine initiation
  publication-title: Int Clin Psychopharmacol
– volume: 9
  start-page: 119
  year: 2013
  end-page: 131
  article-title: Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta‐analysis
  publication-title: Neuropsychiatr Dis Treat
– volume: 82
  start-page: 107
  year: 2006
  end-page: 114
  article-title: Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first‐ vs. second‐generation antipsychotics
  publication-title: Schizophr Res
– volume: 95
  start-page: 617
  year: 2014
  end-page: 626
  article-title: Methods for measuring, enhancing, and accounting for medication adherence in clinical trials
  publication-title: Clin Pharmacol Ther
– volume: 158
  start-page: 518
  year: 2001
  end-page: 526
  article-title: Effectiveness of second‐generation antipsychotics in patients with treatment‐resistant schizophrenia: a review and meta‐analysis of randomized trials
  publication-title: Am J Psychiatry
– volume: 22
  start-page: 1349
  year: 2016
  end-page: 1361
  article-title: Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia
  publication-title: J Manag Care Spec Pharm
– year: 1976
– volume: 25
  start-page: 1242
  year: 2005
  end-page: 1247
  article-title: Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy
  publication-title: Pharmacotherapy
– volume: 163
  start-page: 600
  year: 2006
  end-page: 610
  article-title: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
  publication-title: Am J Psychiatry
– volume: 13
  start-page: 177
  year: 1983
  end-page: 183
  article-title: A self‐report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity
  publication-title: Psychol Med
– volume: 3
  start-page: 200
  year: 2020
  end-page: 218
  article-title: Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
  publication-title: Ther Adv Psychopharmacol
– volume: 34
  start-page: 579
  year: 2020
  end-page: 598
  article-title: Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta‐analysis
  publication-title: CNS Drugs
– ident: e_1_2_9_12_1
  doi: 10.1016/j.schres.2006.11.015
– ident: e_1_2_9_25_1
– ident: e_1_2_9_34_1
  doi: 10.2147/NDT.S39303
– ident: e_1_2_9_8_1
  doi: 10.4088/JCP.v65n0311
– volume-title: MacArthur competence assessment tool for clinical research (MacCAT‐CR)
  year: 2001
  ident: e_1_2_9_23_1
– ident: e_1_2_9_20_1
  doi: 10.1097/YIC.0000000000000188
– ident: e_1_2_9_27_1
  doi: 10.1192/bjp.156.6.798
– ident: e_1_2_9_32_1
  doi: 10.1016/j.schres.2013.02.016
– volume-title: ECDEU assessment manual for psychopharmacology
  year: 1976
  ident: e_1_2_9_24_1
– ident: e_1_2_9_30_1
  doi: 10.4088/JCP.v69n0107
– ident: e_1_2_9_13_1
  doi: 10.1016/j.schres.2005.10.015
– ident: e_1_2_9_11_1
  doi: 10.1016/j.schres.2017.06.026
– ident: e_1_2_9_16_1
  doi: 10.1176/appi.ajp.158.8.1305
– ident: e_1_2_9_33_1
  doi: 10.1016/j.ijcard.2016.04.082
– ident: e_1_2_9_18_1
  doi: 10.1093/schbul/sbj067
– volume: 59
  start-page: 22
  year: 1998
  ident: e_1_2_9_22_1
  article-title: The mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10
  publication-title: J Clin Psychiatry
– ident: e_1_2_9_15_1
  doi: 10.1001/archpsyc.1988.01800330013001
– ident: e_1_2_9_5_1
  doi: 10.1038/clpt.2014.59
– ident: e_1_2_9_7_1
  doi: 10.1016/j.psychres.2004.11.002
– ident: e_1_2_9_19_1
  doi: 10.1176/ajp.2006.163.4.600
– ident: e_1_2_9_6_1
  doi: 10.1016/j.schres.2008.09.007
– ident: e_1_2_9_14_1
  doi: 10.1007/s40263-020-00713-9
– ident: e_1_2_9_17_1
  doi: 10.1176/appi.ajp.158.4.518
– ident: e_1_2_9_2_1
  doi: 10.1177/2045125312474019
– start-page: 1
  year: 2009
  ident: e_1_2_9_28_1
  article-title: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness
  publication-title: J Clin Psychiatry
– ident: e_1_2_9_4_1
  doi: 10.2147/PPA.S124658
– ident: e_1_2_9_35_1
  doi: 10.18553/jmcp.2016.22.11.1349
– ident: e_1_2_9_10_1
  doi: 10.1016/j.schres.2011.11.008
– ident: e_1_2_9_26_1
  doi: 10.1017/S0033291700050182
– ident: e_1_2_9_9_1
  doi: 10.1176/ps.2007.58.9.1187
– ident: e_1_2_9_29_1
  doi: 10.1176/appi.ps.55.8.886
– ident: e_1_2_9_31_1
  doi: 10.1592/phco.2005.25.9.1242
– ident: e_1_2_9_3_1
  doi: 10.1016/j.psychres.2014.11.002
– ident: e_1_2_9_21_1
  doi: 10.1016/j.psychres.2019.01.110
SSID ssib001098819
ssj0005108
ssib020716634
ssib053816035
ssib002667577
ssib006541434
ssib053816034
ssib006541432
ssib006541433
ssib017358148
ssib058492090
ssib000381225
Score 2.4480522
Snippet Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event...
BackgroundTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event...
To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System...
SourceID proquest
crossref
wiley
nii
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 87
SubjectTerms adherence
Adult
Antipsychotic Agents
Antipsychotics
Clozapine
compliance
Female
Humans
Male
Medication Adherence
Mental disorders
Microelectromechanical systems
Outpatients
Prospective Studies
Psychotropic drugs
Schizophrenia
Title Adherence to clozapine vs. other antipsychotics in schizophrenia
URI https://cir.nii.ac.jp/crid/1872272492558869760
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Facps.13208
https://www.proquest.com/docview/2435016664
https://www.proquest.com/docview/2420632747
Volume 142
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB_8APHF8_zAeioRfVHoss0mTQs-uHq3iKCIH7AvUpK0xeLSXeyuD_71zvRjXQ8R7l5KaSYlzWSS3zTzmwAcekRf9LVwcWlJXBF7aFJKCFcqmwSprzxpie98de1fPIjLvuzPwUnDhanyQ0x_uJFllPM1Gbg2xYyRazsqWkQAJqYvBWsRIrr9yB2Fg62ahtFfRhewX-cmpTCej6qfVqP5PMs-Ac1ZuFquN70f8Ni0tAozeW5NxqZl3_5K4vi_n7IKKzUQZd1q5PyEuSRfg6Wreqt9HU678VNFBWTjIbOD4ZseYQF7LVqsZG0x1ElWk7gyW7AsZ8VsBN8GPPT-3J9fuPVxC67FRSlwfROnSRj7KpWpUmlslBEp4gcjbahjxH1WKSt5wmNElQTblMGHJoxDrCaDtLMJC_kwT7aA8UB3uG2H3DNSqLaHrzLKcm07OkQPKnXgqOn2yNa5yOlIjEHU-CTUJVHZJQ4cTGVHVQaOL6V2UXv4Mrp6geJcUS5EKYPAR8TVdmCn0WtUW2kRcUHbqujACQf2p8VoX7RpovNkOCEZjiiOfHcHjkslftOKqHt-c1febf-L8C9Y5uTGl3GFO7Awfpkku4h1xmYPFrtnv896e-XYfge0B_e7
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4NkICXARto2Sh42l5AStW4dpy8rSpUhVGEBkh9i2InEdFQWpGWB_567pz0BwhNYi9RFJ-jxOezv7PvPgP89Ch90Y-Fi1NL6orEQ5NSQrhSmTTIfOVJQ_nOg0u_fyvOh3JYx-ZQLkzFDzFfcCPLsOM1GTgtSC9ZeWzGZZMygIMVWKMjvYk6_-TPgj0Ku1s1EKPHjE7gsGYnpUCeRd0X89FKkecvoOYyYLUzTm-rOla1tESFFGjytzmd6KZ5ekXj-N8_sw0fayzKOlXn2YEPafEJ1gf1bvtn-NVJ7qpsQDYZMXM_eorHWMAeyyaziVsM1ZLXeVy5KVlesHI5iG8XbnunN92-W5-44BqclwLX10mWhomvMpkplSVaaZEhhNDShHGC0M8oZSRPeYLAkpCb0vhQh0mI1WSQtfdgtRgV6RdgPIjb3LRC7mkpVMvDV2lleGzacYhOVObA0azdI1PTkdOpGPfRzC2hJolskzjwYy47rkg43pRqoPrwZXT1AsW5IjpEKYPAR9DVcmB_ptioNtQy4oJ2VtGHEw58nxejidG-SVykoynJcARy5L47cGy1-I-viDrdq2t79_U9woew0b8ZXEQXZ5e_v8EmJ6_ehhnuw-rkYZo2EPpM9IHt4M9oCPpl
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDkpf1m1dqbe01WhfNnCIFcmyoQ8LbUP30VL6AXkZxpIsZlacMCd9yF_fO3-k6SiD7cUY6yRknU73O-nuBHAYUPhimAofVUvmCxugSCkhfKlMFrlQBdJQvPP5RXh2K76O5GgFjtpYmDo_xGLDjSSjWq9JwCfWLQl5aiZllwKAo1V4IcJeTBc3nFw9Jo_C2Vavw2gwow04apKTkh_PY90n6mi1yPMnSHMZr1YKZ7gJP9qu1n4mv7qzqe6a-R9ZHP_3X17BywaJskE9dV7DSla8gfXz5qx9Cz4P7M86FpBNx8zcjefpBAvYfdllVdgWQ6bkTRRXbkqWF6xcduF7C7fD05vjM7-5b8E3qJUiP9TWZbENlZNOKWe10sIhgNDSxKlF4GeUMpJn3CKsJNymNH7UsY2xmoxcfxvWinGR7QDjUdrnphfzQEuhegE2pZXhqemnMZpQzoOP7bAnpklGTndi3CWtUUJDklRD4sHBgnZSp-B4lmoXuYeN0TOIFOeKkiFKGUUhQq6eB52Wr0kjpmXCBZ2rogUnPPiwKEYBo1OTtMjGM6LhCOPIePfgU8XEv_QiGRxfXldv7_6FeB_WL0-GyfcvF9_ewwYnk77yMezA2vT3LNtF3DPVe9X0fgB5rPkU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+clozapine+vs.+other+antipsychotics+in+schizophrenia&rft.jtitle=Acta+psychiatrica+Scandinavica&rft.au=Takeuchi%2C+H.&rft.au=Borlido%2C+C.&rft.au=Sanches%2C+M.&rft.au=Teo%2C+C.&rft.date=2020-08-01&rft.issn=0001-690X&rft.eissn=1600-0447&rft.volume=142&rft.issue=2&rft.spage=87&rft.epage=95&rft_id=info:doi/10.1111%2Facps.13208&rft.externalDBID=10.1111%252Facps.13208&rft.externalDocID=ACPS13208
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-690X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-690X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-690X&client=summon